Tag:

GV1001

Latest Headlines

Latest Headlines

Cancer vaccines report mixed fortunes at ASCO

June 6, 2013 | By
At the cancer conference ASCO, researchers reported weak Phase III results for a telomerase peptide vaccine, GV1001, in pancreatic cancer patients. Most other cancer vaccines presented at the conference are at earlier stages of development.

U.K. researchers report big immunotherapy flop for long-sought cancer vaccine

FierceBiotech | June 3, 2013
Not all the immunotherapies have impressed at ASCO in Chicago. A large Phase III study of the immunotherapy GV1001 showed an insignificant difference in overall survival between pancreatic cancer patients treated with the experimental treatment and those taking standard chemotherapy.
Related Tags
Press Releases
  • U.S. FDA Panel Supports Medtronic, Inc. (MDT) Pacemaker
  • Atritech, Inc. Announces FDA Regulatory Update; Confirmatory Study Required for Final FDA Approval
  • FDA APPROVES FIRST OF ITS KIND, FULLY IMPLANTABLE (SURGICALLY), INVISIBLE, PROSTHETIC HEARING RESTORATION DEVICE
  • CryoLife Comments on Status of Medafor Distribution Agreement
  • FDA Statement on Boston Scientific Recall of Implantable Cardioverter Defibrillators
  • More Press Releases
Featured Jobs
  • Senior Director, Payer & PBM Accounts - Northeast Job
    Celgene Corporation - Summit NJ US
  • Senior Strategic Planner, Global Biologics - 13000003MJ
    Abbvie - Worcester MA United States
  • VICE PRESIDENT, CLINICAL RESEARCH
    Soligenix, Inc. - Princeton NJ USA
  • Clinical Nurse Consultant - Chicago Job
    Celgene Corporation - Chicago IL US
  • Vice President, Global Medical Affairs - Multiple Myeloma Job
    Celgene Corporation - Summit NJ US
Sponsored Links